Literature DB >> 19533070

[Changes in treatment of squamous cell carcinoma over time. A process analysis].

C Rogalski1, G Gelbrich, R Renner, K Hebestreit, U Paasch.   

Abstract

BACKGROUND: The incidence of squamous cell carcinoma is rapidly increasing and requires process-optimized treatment dependent on the course of the patient's individual disease. Patient-based data on squamous cell carcinoma were used to analyze the treatment modalities before DRGs were introduced, after their introduction and after discussion about process-optimization in context of clinical pathways. PATIENTS AND METHODS: From the recorded data in the department of dermatology, all squamous cell carcinoma cases were identified and evaluated. In addition to patient characteristics, parameters describing the process, for example, length of stay in hospital, pre- and post-interventional days, were collected.
RESULTS: Between 1998-2002, 2004-2006 and January to June 2007, 658 patients were treated for squamous cell carcinoma. In contrast to the times before DRGs, the treatment process has been significantly optimized, reducing the pre- and post-operative days and thus the duration of stay. Analysis of clinical pathways as part of the continuous improvement process was hardly able to detect further improvement. However, the weekly distribution of the admitted patients has been improved.
CONCLUSIONS: Patients with squamous cell carcinoma requiring surgical excision benefit from an optimized process, just as do impatient facilities. However, optimized treatment modalities carry hardly any potential of improvement by the invention of clinical pathways.

Entities:  

Mesh:

Year:  2009        PMID: 19533070     DOI: 10.1007/s00105-009-1774-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  9 in total

1.  Clinical pathway compliance and quality improvement.

Authors:  Leigh Kinsman
Journal:  Nurs Stand       Date:  2004 Jan 14-20

Review 2.  Computerised clinical pathway management systems and the implications.

Authors:  S Chu
Journal:  Collegian       Date:  2001-04       Impact factor: 2.573

3.  Evaluation of a bed utilization system in a surgical nursing section.

Authors:  F M Rivers; S M Lavallee; K M Nenninger; D Nichols
Journal:  Mil Med       Date:  1998-12       Impact factor: 1.437

4.  [Desmoplastic squamous epithelial carcinoma of the skin and lower lip. A morphologic entity with great risk of metastasis and recurrence].

Authors:  H Breuninger; J Holzschuh; G Schaumburg Lever; W Schippert; H P Horny
Journal:  Hautarzt       Date:  1998-02       Impact factor: 0.751

Review 5.  Diagnosing skin malignancy: assessment of predictive clinical criteria and risk factors.

Authors:  Scott M Strayer; Peter L Reynolds
Journal:  J Fam Pract       Date:  2003-03       Impact factor: 0.493

6.  Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996.

Authors:  R B Harris; K Griffith; T E Moon
Journal:  J Am Acad Dermatol       Date:  2001-10       Impact factor: 11.527

7.  Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy.

Authors:  A L Caforio; A B Fortina; S Piaserico; M Alaibac; F Tona; G Feltrin; E Pompei; L Testolin; A Gambino; S D Volta; G Thiene; D Casarotto; A Peserico
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

8.  Reconceptualising clinical pathway system design.

Authors:  S Chu
Journal:  Collegian       Date:  2001-01       Impact factor: 2.573

9.  Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer).

Authors:  A Katalinic; U Kunze; T Schäfer
Journal:  Br J Dermatol       Date:  2003-12       Impact factor: 9.302

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.